• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA grants priority review for Daiichi Sankyo’s AML medicine

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 25, 2022 at 11:02: AM
via The US Food and Drug Administration (FDA) has granted priority review for Daiichi Sankyo’s quizartinib along with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy to treat newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

article source
 




Top Bottom
Back
Quote